D. Zucman, F. Boué, P. Miailhes, E. Billaud, H. Aumaître et al., Clinical Centres (ward/participating physicians, APHP Cochin

, APHP Pitié-Salpétrière

, APHP Pitié-Salpétrière

, Virologie: C. Tamalet)

, Virologie: C. Le Pendeven

, Toulouse (Maladies Infectieuses et Tropicales: B. Marchou; Hépato-gastro-entérologie: L. Alric, K. Barange, S. Metivier; Anatomo-pathologie, Virologie: F. Larroquette

, Infectiologie: A. Naqvi, V. Rio; Anatomo-pathologie, Virologie: C. Partouche)

, Médecine Interne-Unité VIH: O. Bouchaud; Anatomo-pathologie: M. Ziol

H. Joseph-ducuing, ;. M. Uzan, A. Bicart-see, D. Garipuy, and M. J. Ferro-collados,

. Anatomo-pathologie, Virologie: F. Nicot

A. Bichat and -. , Virologie: G. Alexandre

A. Saint-louis,

A. Saint-antoine, ;. K. Lacombe, and J. Bottero, Maladies Infectieuses et Tropicales

J. Krause, P. M. Girard, :. D. Anatomo-pathologie, P. Wendum, J. Cervera et al., Virologie: C. Viala)

A. Bicêtre, :. C. Paris-(médecine-interne, Y. Goujard, E. Quertainmont, and . Teicher, Virologie: C. Pallier; Maladies Infectieuses: D. Vittecoq

A. Necker, . Paris-(maladies-infectieuses, :. O. Tropicales, C. Lortholary, C. Duvivier et al., Virologie: V. Avettand-Fenoel, A. Mélard

A. Ochoa, E. Blanchard, S. Castet-lafarie, C. Cazanave, D. Malvy et al., Bordeaux (Maladies Infectieuses et Tropicales: D. Neau

:. P. Anatomo-pathologie and . Bioulac-sage, Virologie: P. Trimoulet, S. Reigadas

D. Lacoste, F. Bonnet, N. Bernard, M. Hessamfar, J. et al., Médecine Interne et Maladies Infectieuses: Médecine Interne et Maladies Infectieuses: P. Morlat

. Hôpital-du-haut-levêque, :. J. Bordeaux-(médecine-interne, J. F. Pellegrin, E. Viallard, C. Lazzaro et al., Virologie: P. Trimoulet, S. Reigadas

F. Hôpital, :. D. Suresnes-(médecine-interne, C. Zucman, and . Majerholc, Virologie: E. Farfour)

. Aphp-antoine-béclère, :. F. Clamart-(médecine-interne, J. Boué, I. Polo-devoto, V. Kansau et al., Virologie : C. Deback)

F. Raffi, C. Allavena, V. Reliquet, D. Boutoille, and C. Biron, Nantes (Maladies Infectieuses et Tropicales: E. Billaud

:. A. Virologie, L. Rodallec, and . Le-guen,

. Hôpital-de-la-croix-rousse, Lyon (Maladies Infectieuses et Tropicales: P

D. Miailhes, C. Peyramond, F. Chidiac, F. Ader, A. Biron et al.,

. Chu-dijon, :. Dijon-(département-d'infectiologie, L. Piroth, P. Chavanet, M. Duong-van-huyen et al., Simonet-Lann, D. Croisier-Bertin

C. H. Perpignan, Perpignan (Maladies infectieuses et tropicales: H. Aumaître)

;. F. Chu-robert-debré, D. Bani-sadr, . Lambert, J. L. Nguyen, and . Berger, Reims (Médecine interne, maladies infectieuses et immunologie clinique

D. Rey, . Partisani, C. Ml-batard, . Cheneau, . Priester et al., Virologie: P Gantner et S Fafi-Kremer)

B. Bernard, ;. F. Roustant, I. Kmiec, L. Traore, S. Lepuil et al., Data collection
URL : https://hal.archives-ouvertes.fr/hal-01678034

O. Makhoukhi, R. Braik, M. P. Bayoud, V. L. Pietri, D. Baut et al., Management

S. Mora, C. Nordmann, P. Protopopescu, B. Roux, S. Spire et al., We especially thank all physicians and nurses who are involved in the follow-up of the cohort and all patients who took part in this study

J. Pawlotsky, Pathophysiology of hepatitis C virus infection and related liver disease, Trends Microbiol, vol.12, pp.96-102, 2004.
DOI : 10.1016/j.tim.2003.12.005

G. Castello, S. Scala, G. Palmieri, S. A. Curley, and F. Izzo, HCV-related hepatocellular carcinoma: From chronic inflammation to cancer, Clin. Immunol, vol.134, pp.237-250, 2010.
DOI : 10.1016/j.clim.2009.10.007

N. Moqueet, C. Kanagaratham, M. J. Gill, M. Hull, S. Walmsley et al., Canadian Co-infection Cohort Study (CTN 222). A prognostic model for development of significant liver fibrosis in HIV-hepatitis C co-infection, PLoS ONE, vol.12, 2017.

P. Marcellin, T. Asselah, and N. Boyer, Fibrosis and disease progression in hepatitis C, Hepatology, vol.36, pp.47-56, 2002.
DOI : 10.1053/jhep.2002.36993

T. Poynard, V. Ratziu, F. Charlotte, Z. Goodman, J. Mchutchison et al., Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C, J. Hepatol, vol.34, pp.730-739, 2001.

K. Joshi, A. Kohli, R. Manch, and R. Gish, Alcoholic Liver Disease: High Risk or Low Risk for Developing Hepatocellular Carcinoma? Clin. Liver Dis, vol.20, pp.563-580, 2016.

F. Liu, X. Wang, G. Wu, L. Chen, P. Hu et al., Coffee Consumption Decreases Risks for Hepatic Fibrosis and Cirrhosis: A Meta-Analysis, PLoS ONE, vol.10, 2015.
DOI : 10.1371/journal.pone.0142457

URL : https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0142457&type=printable

L. J. Alferink, J. Fittipaldi, J. C. Kiefte-de-jong, P. Taimr, B. E. Hansen et al., Coffee and herbal tea consumption is associated with lower liver stiffness in the general population: The Rotterdam study, J. Hepatol, vol.67, pp.339-348, 2017.

M. A. Heckman, J. Weil, and E. G. De-mejia, Caffeine (1, 3, 7-trimethylxanthine) in Foods: A Comprehensive Review on Consumption, Functionality, Safety, and Regulatory Matters, J. Food Sci, vol.75, pp.77-87, 2010.

J. Godos, F. R. Pluchinotta, S. Marventano, S. Buscemi, G. Li-volti et al., Coffee components and cardiovascular risk: Beneficial and detrimental effects, Int. J. Food Sci. Nutr, vol.65, pp.925-936, 2014.

G. Grosso, J. Godos, F. Galvano, E. L. Giovannucci, and . Coffee, Caffeine, and Health Outcomes: An Umbrella Review, Annu. Rev. Nutr, vol.37, pp.131-156, 2017.

G. Grosso, A. Micek, J. Godos, S. Sciacca, A. Pajak et al., Coffee consumption and risk of all-cause, cardiovascular, and cancer mortality in smokers and non-smokers: A dose-response meta-analysis, Eur. J. Epidemiol, vol.31, pp.1191-1205, 2016.

G. Alicandro, A. Tavani, and C. Vecchia, Coffee and cancer risk: A summary overview, Eur. J. Cancer Prev, vol.26, pp.424-432, 2017.

M. Ding, S. N. Bhupathiraju, A. Satija, R. M. Van-dam, and F. B. Hu, Long-term coffee consumption and risk of cardiovascular disease: A systematic review and a dose-response meta-analysis of prospective cohort studies, Circulation, vol.129, pp.643-659, 2014.

M. P. Carrieri, C. Lions, P. Sogni, M. Winnock, P. Roux et al., ANRS CO13 HEPAVIH Study Group. Association between elevated coffee consumption and daily chocolate intake with normal liver enzymes in HIV-HCV infected individuals: Results from the ANRS CO13 HEPAVIH cohort study, J. Hepatol, vol.60, pp.46-53, 2014.

M. G. Oh, M. A. Han, M. W. Kim, C. G. Park, Y. D. Kim et al., Coffee consumption is associated with lower serum aminotransferases in the general Korean population and in those at high risk for hepatic disease, Asia Pac. J. Clin. Nutr, vol.25, pp.767-775, 2016.

F. Morisco, V. Lembo, G. Mazzone, S. Camera, and N. Caporaso, Coffee and liver health, J. Clin. Gastroenterol, vol.48, 2014.

T. Stroffolini, G. Cotticelli, E. Medda, M. Niosi, C. Del-vecchio-blanco et al., Interaction of alcohol intake and cofactors on the risk of cirrhosis, Liver Int, vol.30, pp.867-870, 2010.

N. D. Freedman, J. E. Everhart, K. L. Lindsay, M. G. Ghany, T. M. Curto et al., Coffee Intake Is Associated with Lower Rates of Liver Disease Progression in Chronic Hepatitis C, Hepatology, vol.50, pp.1360-1369, 2009.

M. P. Carrieri, J. Cohen, D. Salmon-ceron, and M. Winnock, Coffee consumption and reduced self-reported side effects in HIV-HCV co-infected patients during PEG-IFN and ribavirin treatment: Results from ANRS CO13 HEPAVIH, J. Hepatol, vol.56, pp.745-747, 2012.

S. G. Shim, D. W. Jun, E. K. Kim, W. K. Saeed, K. N. Lee et al., Caffeine attenuates liver fibrosis via defective adhesion of hepatic stellate cells in cirrhotic model, J. Gastroenterol. Hepatol, vol.28, pp.1877-1884, 2013.

K. Bai, Q. Cai, Y. Jiang, and L. Lv, Coffee consumption and risk of hepatocellular carcinoma: A meta-analysis of eleven epidemiological studies, OncoTargets Ther, vol.9, pp.4369-4375, 2016.

M. Loko, D. Salmon, P. Carrieri, M. Winnock, M. Mora et al., The French national prospective cohort of patients co-infected with HIV and HCV, ANRS CO13 HEPAVIH): Early findings, vol.10, p.303, 2006.
URL : https://hal.archives-ouvertes.fr/pasteur-01070193

R. K. Sterling, E. Lissen, N. Clumeck, R. Sola, M. C. Correa et al., Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection, Hepatology, vol.43, pp.1317-1325, 2006.

M. P. Carrieri, C. Protopopescu, F. Marcellin, S. Rosellini, L. Wittkop et al., Protective effect of coffee consumption on all-cause mortality of French HIV-HCV co-infected patients, J. Hepatol, 2017.

P. Labarga, J. V. Fernandez-montero, C. De-mendoza, P. Barreiro, J. Pinilla et al., Liver fibrosis progression despite HCV cure with antiviral therapy in HIV-HCV-coinfected patients, Antivir. Ther, vol.20, pp.329-334, 2015.

I. Oze, K. Matsuo, D. Kawakita, S. Hosono, H. Ito et al., Coffee and green tea consumption is associated with upper aerodigestive tract cancer in Japan, Int. J. Cancer, vol.135, pp.391-400, 2014.

G. Grosso, U. Stepaniak, A. Micek, D. Stefler, M. Bobak et al., Coffee consumption and mortality in three Eastern European countries: Results from the HAPIEE (Health, Alcohol and Psychosocial factors in Eastern Europe) study. Public Health Nutr, vol.20, pp.82-91, 2017.

O. J. Kennedy, P. Roderick, R. Buchanan, J. A. Fallowfield, P. C. Hayes et al., Systematic review with meta-analysis: Coffee consumption and the risk of cirrhosis, Aliment. Pharmacol. Ther, vol.43, pp.562-574, 2016.

V. W. Setiawan, J. Porcel, P. Wei, D. O. Stram, N. Noureddin et al., Coffee Drinking and Alcoholic and Nonalcoholic Fatty Liver Diseases and Viral Hepatitis in the Multiethnic Cohort, Clin. Gastroenterol. Hepatol, vol.15, pp.1305-1307, 2017.

V. Jaruvongvanich, A. Sanguankeo, N. Klomjit, and S. Upala, Effects of caffeine consumption in patients with chronic hepatitis C: A systematic review and meta-analysis, Clin. Res. Hepatol. Gastroenterol, vol.41, pp.46-55, 2017.

S. C. Larsson and A. Wolk, Coffee Consumption and Risk of Liver Cancer: A Meta-Analysis, Gastroenterology, vol.132, pp.1740-1745, 2007.

K. Nieber, The Impact of Coffee on Health, vol.83, pp.1256-1263, 2017.

H. Shi, L. Dong, J. Jiang, J. Zhao, G. Zhao et al., Chlorogenic acid reduces liver inflammation and fibrosis through inhibition of toll-like receptor 4 signaling pathway, Toxicology, vol.303, pp.107-114, 2013.

J. K. Lim, J. P. Tate, S. L. Fultz, J. L. Goulet, J. Conigliaro et al., Relationship between alcohol use categories and noninvasive markers of advanced hepatic fibrosis in HIV-infected, chronic hepatitis C virus-infected, and uninfected patients, Clin. Infect. Dis, vol.58, pp.1449-1458, 2014.

F. Marcellin, P. Roux, M. Loko, C. Lions, A. Caumont-prim et al., High levels of alcohol consumption increase the risk of advanced hepatic fibrosis in HIV/hepatitis C virus-coinfected patients: A sex-based analysis using transient elastography at enrollment in the HEPAVIH ANRS CO13 cohort, Clin. Infect. Dis, vol.59, pp.1190-1192, 2014.
URL : https://hal.archives-ouvertes.fr/inserm-01997182

A. Balasubramanian, M. Koziel, J. E. Groopman, and R. K. Ganju, Molecular mechanism of hepatic injury in coinfection with hepatitis C virus and HIV, Clin. Infect. Dis, pp.32-37, 2005.

C. Mascia, M. Lichtner, P. Zuccalà, S. Vita, T. Tieghi et al., Active HCV infection is associated with increased circulating levels of interferon-gamma (IFN-?)-inducible protein-10 (IP-10), soluble CD163 and inflammatory monocytes regardless of liver fibrosis and HIV coinfection, Clin. Res. Hepatol. Gastroenterol, vol.41, pp.644-655, 2017.

A. A. Negash, H. J. Ramos, N. Crochet, D. T. Lau, B. Doehle et al., IL-1? Production through the NLRP3 Inflammasome by Hepatic Macrophages Links Hepatitis C Virus Infection with Liver Inflammation and Disease, PLoS Pathog, vol.9, 2013.

A. J. Czaja, Hepatic inflammation and progressive liver fibrosis in chronic liver disease, World J. Gastroenterol, vol.20, pp.2515-2532, 2014.
DOI : 10.3748/wjg.v20.i10.2515

URL : https://doi.org/10.3748/wjg.v20.i10.2515

C. Delgado-andrade, J. A. Rufián-henares, and F. J. Morales, Assessing the antioxidant activity of melanoidins from coffee brews by different antioxidant methods, J. Agric. Food Chem, vol.53, pp.7832-7836, 2005.

Y. Gutiérrez-grobe, N. Chávez-tapia, V. Sánchez-valle, J. G. Gavilanes-espinar, G. Ponciano-rodríguez et al., High coffee intake is associated with lower grade nonalcoholic fatty liver disease: The role of peripheral antioxidant activity, Ann. Hepatol, vol.11, pp.350-355, 2012.

G. D. Lundberg, A Supplement That May Block. The Toxic Effects of Alcohol, 2017.

P. Labarga, J. V. Fernandez-montero, P. Barreiro, J. Pinilla, E. Vispo et al., Changes in liver fibrosis in HIV/HCV-coinfected patients following different outcomes with peginterferon plus ribavirin therapy, J. Viral Hepat, vol.21, pp.475-479, 2014.

J. V. Fernández-montero, P. Barreiro, E. Vispo, P. Labarga, C. Sánchez-parra et al., Liver fibrosis progression in HIV-HCV-coinfected patients treated with distinct antiretroviral drugs and impact of pegylated interferon/ribavirin therapy, Antiviral Ther, vol.19, pp.287-292, 2014.

A. Cohort, Regression of liver stiffness after sustained hepatitis C virus (HCV) virological responses among HIV/HCV-coinfected patients, AIDS, vol.29, pp.1821-1830, 2015.

R. J. Fontana, H. L. Bonkovsky, D. Naishadham, J. L. Dienstag, R. K. Sterling et al., Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis, Clin. Gastroenterol. Hepatol, vol.7, pp.219-226, 2009.

J. Berenguer, J. Alvarez-pellicer, P. M. Martín, J. López-aldeguer, M. A. Von-wichmann et al., Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus, Hepatology, vol.50, pp.407-413, 2009.
DOI : 10.1002/hep.23020

Y. Benhamou, M. Bochet, V. Martino, F. Charlotte, F. Azria et al., Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group, Hepatology, vol.30, pp.1054-1058, 1999.

C. S. Graham, L. R. Baden, E. Yu, J. M. Mrus, J. Carnie et al., Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: A meta-analysis, Clin. Infect. Dis, vol.33, pp.562-569, 2001.

N. Bräu, M. Salvatore, C. F. Ríos-bedoya, A. Fernández-carbia, F. Paronetto et al., Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy, J. Hepatol, vol.44, pp.47-55, 2006.

F. Bani-sadr, N. Lapidus, P. Bedossa, C. M. De-boever, C. Perronne et al., French National Agency for Research on AIDS; et al. Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: Analysis of risk factors, Clin. Infect. Dis, vol.46, pp.768-774, 2008.

T. Suárez-zarracina, E. Valle-garay, J. Collazos, A. H. Montes, V. Cárcaba et al., Didanosine (ddI) associates with increased liver fibrosis in adult HIV-HCV coinfected patients, J. Viral Hepat, vol.19, pp.685-693, 2012.

H. K. Dyal, M. Aguilar, T. Bhuket, B. Liu, E. W. Holt et al., Concurrent Obesity, Diabetes, and Steatosis Increase Risk of Advanced Fibrosis among HCV Patients: A Systematic Review, Dig. Dis. Sci, vol.60, pp.2813-2824, 2015.

A. El-ray, T. Asselah, R. Moucari, M. El-ghannam, A. A. Taha et al., Insulin resistance: A major factor associated with significant liver fibrosis in Egyptian patients with genotype 4 chronic hepatitis C, Eur. J. Gastroenterol. Hepatol, vol.25, pp.421-427, 2013.

S. X. Hu, N. L. Kyulo, V. W. Xia, D. J. Hillebrand, and K. Q. Hu, Factors Associated with Hepatic Fibrosis in Patients with Chronic Hepatitis C: A Retrospective Study of a Large Cohort of U.S. Patients, J. Clin. Gastroenterol, vol.43, pp.758-764, 2009.

Z. M. Younossi, A. J. Mccullough, J. P. Ong, D. S. Barnes, A. Post et al., Obesity and non-alcoholic fatty liver disease in chronic hepatitis C, J. Clin. Gastroenterol, vol.38, pp.705-709, 2004.

O. J. Kennedy, P. Roderick, R. Buchanan, J. A. Fallowfield, P. C. Hayes et al., Coffee, including caffeinated and decaffeinated coffee, and the risk of hepatocellular carcinoma: A systematic review and dose-response meta-analysis, BMJ Open, vol.7, 2017.

J. Godos, A. Micek, M. Marranzano, F. Salomone, D. D. Rio et al., Coffee Consumption and Risk of Biliary Tract Cancers and Liver Cancer: A Dose-Response Meta-Analysis of Prospective Cohort Studies, Nutrients, vol.9, p.950, 2017.